Yes very encouraging......deduct their cash backing - legitimately convert to US dollars, for Pharma discussion purposes ....IMU etc. Really good.
Also from that Clinical.Trials.gov - this is the highly sophisticated biomarker studies.... these days, of how patient progress is monitored.
Secondary Outcome Measures :
- Chimeric antigen receptor (CAR) T cell [ Time Frame: 15 years ]
Will assess its levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per ul by flowcytometry). Statistical and graphical methods will be used.- Endogenous T cell [ Time Frame: 15 years ]
Will assess its level and phenotype detected in TCF, PB, and CSF (absolute number per ul by flowcytometry). Statistical and graphical methods will be used.- Cytokine levels in TCF, PB and CSF [ Time Frame: 15 years ]
- Progression free survival time [ Time Frame: At 6 months ]
- Disease response [ Time Frame: At 6 months ]
Will be assessed by modified Response Assessment in Neuro-Oncology Criteria (RANO) criteria with the need for bevacizumab as an additional indicator of progression.- Overall survival (OS) [ Time Frame: At 9 months ]
Kaplan Meier methods will be used to estimate median OS and graph the results.- CAR T cells detected in tumor tissue [ Time Frame: 15 years ]
Will be assessed by immunohistochemistry.- Chlorotoxin-targeted antigen expression levels in tumor tissue [ Time Frame: 15 years ]
Will assess the pathology H score.- Biomathematical modeling of tumor growth [ Time Frame: 15 years ]
Will assess perfusion and growth parameters based on serial brain magnetic resonance imaging (MRI)s.
- Forums
- ASX - By Stock
- CHM
- Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial
Ann: Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial, page-6
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CHM (ASX) Chart |
Day chart unavailable